Introduction
The cytochrome P450 (CYP) superfamily is composed of haem proteins that participate in the oxidation of a wide range of compounds. The mechanisms that regulate the expression of specific P450 genes are quite complex, as required to vary the isoenzyme profile and amounts depending on for example the cell type, sex, stage of development, inflammation and other forms of stress, and induction by xenobiotics. Some of the least understood components of this regulatory scheme are the upstream signal transduction events that activate or suppress the expression of a given P450 gene. In recent years, sphingolipids have been found to affect the expression of several isoforms of cytochrome P450; this review will therefore summarize these findings.
Sphingolipids and cell regulation
The lipid backbones (e.g. ceramide, sphingosine and sphingosine 1 -phosphate) of sphingolipids are highly bioactive compounds that modify diverse enzymic activities, transport systems, gene expression, cell growth, differentiation and apoptosis [1] [2] [3] [4] . This system is exemplifed by the 'sphingomyelin-ceramide pathway ', which involves the hydrolysis of sphingomyelin (SM) to ceramide (Cer) on the activation of sphingomyelinases (apparently both neutral and acidic sphingomyelinases) by cytokines [tumour necrosis factor a and interleukin 1p (IL-I/$] [5, 6] and a growing list of other agents, including cell stress [7-91. However, this could be named more broadly a 'sphingomyelin pathway' because some agonists (such as platelet-derived growth factor) are now known also to activate ceramidase and sphingosine kinase, Abbreviations used: AGP, a'-acid glycoprotein; Cer, cerarnide; CYP, cytochrorne P450; IL-IP, interleukin I#?; C2-Cer, Nacetylsphingosine; C2-DHCer, N-acetylsphinganine ; NBD, 7-nitrobenz-boxa-I ,3-diazole; SM, sphingomyelin. 'To whom correspondence should be addressed.
producing the downstream bioactive products sphingosine and sphingosine 1-phosphate [10,11] .
Cytochrome P450 and the acutephase response
During an infection or inflammation, liver decreases the synthesis of ' negative acute-phase proteins' (which include some forms of cytochrome P450), while increasing the synthesis of 'positive acute-phase proteins ', such as a,-acid glycoprotein (AGP) [12] . The major humoral mediators of this acute-phase response for liver are cytokines (e.g. IL-I/? and IL-6) and glucocorticoids at both transcriptional and post-transcriptional levels [12-161. Studies of the effect of inflammation on cytochrome P450 in rats often focus on CYP2Cll because it is a major P450 in male rat liver (involved in drug and steroid hormone clearance), displays constitutively high expression in vivo that can be mimicked by plating rat hepatocytes on Matrigel with insulin as the only added hormone [17] (after 5 days in culture, CYP2Cl1 is expressed at approx. 30 yo of the level in intact liver), and can be affected by stresses such as infection, inflammation and liver regeneration. Furthermore, CYP2C11 mRNA expression can be suppressed by IL-1s in cultured hepatocytes, whereas AGP expression is induced [ 1 8,193. SM hydrolysis and expression of CYPZCl I and AGP Because the ' SM-Cer pathway ' had been found to mediate IL-lB signalling in a number of systems [6, , we examined whether this or a related pathway participates in the IL-1B-induced transcriptional down-regulation of CYP2Cll in rat hepatocytes [19] . This study found all of the initial hallmarks of this pathway: (1) IL-1B stimulated SM hydrolysis; (2) I L -l a increased cellular levels of Cer; (3) the addition of an exogenous sphingomyelinase to hydrolyse SM to Cer replicated the action of IL-lP in the suppression of CYP2Cll and the induction of AGP; and (4) the effects of IL-lB on CYP2C11 and AGP could be mimicked by addition of a short-chain Cer analogue [ Nacetylsphingosine (C2-Cer)l that is more readily delivered to cells than natural long-chain Cer.
Nevertheless, not all of the observations with rat hepatocytes were consistent with Cer acting as the mediator of CYP2Cll down-regulation: (1) the concentrations of IL-18 that suppressed CYP2Cll (approx. 2.5 ng/ml; the dose giving half-maximal response was 1 ng/ml) did not cause an increase in Cer mass, whereas the higher level of I L -l p that induced AGP did elevate Cer; and (2) not only C2-Cer but also N-acetylsphinganine (C2-DHCer) suppressed CYP2C11 expression, which is not typically seen in systems in which Cer is a mediator [14, 15] . In contrast, the induction of AGP displayed the usual selectivity for C2-Cer over C2-DHCer [23, 24] .
These discrepancies were substantiated by examining the time course and stoichiometry of SM hydrolysis and Cer formation [19, 25] . Half of the total SM mass disappeared by 45 min after treatment with IL-lp, whereas there was no elevation in Cer mass within the first 30 min (in some experiments we have seen decreases in Cer). A later increase in Cer accounted for less than half of the decrease in SM, and in studies with 1-2 ng/ml IL-lB, with which there is significant SM hydrolysis and suppression of CYP2C11 [19, 25] , there was no significant elevation in Cer.
The disappearance of SM without the appearance of Cer suggested that the hepatocytes were rapidly hydrolysing Cer to sphingosine; an increase in free sphingosine was found [19, 25] . However, this might not be the only metabolite, because hepatocytes also form sphingosine 1 -phosphate.
T o determine whether sphingosine, as a downstream metabolite of Cer, could be responsible for the suppression of CYP2Cl1, sphingosine was added to the hepatocytes in the presence and the absence of fumonisin B, [25] ; this inhibitor of ceramide synthase [26] was used because sphingosine can be re-acylated to Cer, which would complicate interpretation of the results. Exogenous sphingosine (with or without fumonisin B,) suppressed CYP2C11 expression even more potently than C2-Cer [25] . Thus sphingosine (or its metabolite sphingosine 1 -phosphate) seems to be the actual mediator of CYP2C11 suppression; but, if so, why were C2-Cer and C2-DHCer effective ? Further studies demonstrated that both of these exogenous Cer analogues are rapidly hydrolysed by hepatocytes, resulting in elevations in sphingosine and sphinganine [25] . This also explains the effectiveness of C2-DHCer because it was not acting as C2-Cer itself but rather via sphinganine. The findings of these studies fit Scheme 1, which relates the effects of different concentrations of IL-1 s on cellular sphingolipid amounts and the expression of CYP2C11 and AGP, as well as the effects of exogenous sphingolipids.
Activation of ceramidase(s) by IL-Ig
This model predicts that IL-lP activates ceramidase(s) in an interesting dose-dependent manner. That is, the activation of ceramidase should be greater at lower concentrations of I L -l p (where no Cer accumulates) than at higher concentrations (where increases in Cer were observed). Consistent with this prediction is the observation that the addition of 2.5 ng/ml I L -l p to the hepatocytes caused a 10-fold increase in neutral (pH 7.2) and 2-fold increases in acidic (pH 4.5) ceramidase activities, measured in vitro, whereas 5 ng/ml ILlp caused no activation ( Figure 1) 
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Scheme 2
Model summarizing the likely steps of sphingomyelin metabolism that are involved in the induction of AGP and the suppression of CYP2C I I by IL-I/? in rat hepatocytes
This model demonstrates that IL-Is activates (+) sphingomyelinases but variably affects (+/-) ceramidases (activation occurs only at low concentrations of IL-Is). The model also shows Cer as the mediator of AGP induction, and sphingosine or sphingosine I -phosphate as the mediator of the suppression of CYPZCI I expression. Because both acidic and neutral ceramidases are activated, hydrolysis can occur in plasma membranes and in acidic compartments such as endosomes.
I'u g g -g L l compartments(?)
m -(NBD-Cer, in which NBD stands for 7-nitrobenz-2-oxa-1,3-diazole), which is readily taken up by cells. On the addition of IL-lp, hydrolysis of NBD-Cer to NBD-fatty acid can be followed by HPLC with a fluorescence detector. As shown in Figure 1 (right panel), the hydrolysis of NBD-Cer increased with increasing concentrations of IL-lp until approx. 2.5 ng/ml, after which it decreased to almost the untreated level by 7.5 ng/ml. Although there were slight differences in the doseresponse between these two assays, the bimodal activation of ceramidase activity was apparent in both. This behaviour could account for the lack of accumulation of Cer at the lower concentrations of IL-1p (owing to its hydrolysis) in contrast with its accumulation at higher concentrations.
T h e mechanism(s) for the activation of ceramidase(s) have not been characterized, but 11-1p is known to induce tyrosine phosphorylation/ dephosphorylation [27, 28] . This might have a role in cerarnidase activation (directly or at an upstream step) because vanadate increased ceramidase activities at pH 4.5 and 7.2 almost 6-f0ld, and genistein, an inhibitor of tyrosine kinases, diminished the increase in ceramidase activity in response to 2.5 ng/ml IL-lp.
Changes in the activities of acidic and neutral ceramidases are reminiscent of several reports that both acidic and neutral sphingomyelinases are activated by various agonists [1] [2] [3] [4] . A possible explanation for this is that sphingolipid signalling occurs both on the plasma membrane and in intracellular acidic compartments such as endosomes. A model that includes this possibility and also summarizes the current knowledge about this pathway is shown in Scheme 2. One of the remaining unknowns is how Cer, sphingosine and/or sphingosine 1 -phosphate alter the expression of CYP2C11 and AGP. It is possible that CYP2Cll down-regulation involves the modulation of activator protein 1 by sphingosine 1-phosphate because this transcription factor has been shown to be activated by this lipid [29] , and activator protein 1 has been implicated in the acute-phase response in the liver [30] . Epidermal growth factor has also been shown to downregulate CYP2C11 in hepatocytes [31] , which might indicate the involvement of the Raf/MEKpathway, another pathway that has been associated with sphingolipid signalling [ 13. Furthermore, cells often have multiple signalling pathways for the regulation of important enzymes, so there might be additional mechanisms for regulating CYP2C11, such as via CAMP.
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Other associations between sphingolipid metabolism and cytochrome P450 Santana et al. [32] have provided evidence that Cer mediates the decrease in CYPl9 (aromatase) activity caused by the treatment of rat granulosa cells with tumour necrosis factor a. Experiments to determine whether additional cytochrorne P450 forms are affected by sphingolipids have begun in our laboratories; the findings have been somewhat surprising. We have found (unpublished work) that when HepG2 cells are incubated with inhibitors of de novo sphingolipid biosynthesis, the induction of CYPl A1 by 3-methylcholanthrene is completely blocked. Furthermore, in the presence of these inhibitors, CYPlAl induction can be restored by the addition of exogenous sphingolipids. Thus CYPl A1 is a P450 for which sphingolipids are required for induction, rather than for which sphingolipids suppress expression. T h e mechanism of this interaction is not known but one can envision many ways in which disruption of cellular membranes or intracellular signalling pathways might alter ligand binding by the aryl hydrocarbon receptor and/or its translocation to the nucleus to induce the expression of CYPl A1 . 
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regulatory mechanism(s) evolved to maintain the homeostasis of the endogenous substrate(s) [3] . T h e CYP3A subfamily of CYPs is a group of sequence-related genes expressed at a constitutively high level in human gut and liver [4] . T h e rat CYP3A subfamily is now known to contain five genes (CYPSAI, CYP3A2, CYP3A9, CYP3A18 and CYP3A23), although their constitutive and inducible expression is complicated by developmental and/or strain differences [S]. CYP3Al and CYP3A23 are highly sequence-related genes determined to be constitutively expressed at a low level [S]. CYP3Al/CYP3A23 expression is markedly up-regulated by dexamethasone but not by rifampicin [6] . In humans, three genes are expressed (CYP3A4, CYP3A5 and CYP3A7). CYP3A7 is expressed in fetal liver and is expressed polymorphically at low levels in adult liver [7] . CYP3AS is expressed polymorphically in human liver, has a relatively low substrate turnover and is not elevated to high levels by inducers compared with CYP3A4 [8] . CYP3A4 is the major expressed CYP3A and might even constitute the bulk of total liver CYP; it is prominent in the metabolism of many drugs and is inducible by dexamethasone and rifampicin [6] . T h e complexities of the CYP3A subfamilies ensure that one cannot determine orthologues between species but it is likely
